Morphine inhibits intrahepatic interferon-α expression and enhances complete hepatitis C virus replication

Journal of Infectious Diseases

Volumn 196, Issue 5, 2007, Pages 719-730

  Li, Yuan ^a,b   Ye, Li ^a,b   Peng, Jin Song ^d   Wang, Chuan Qing ^e   Luo, Guang Xiang ^c   Zhang, Ting ^a,b   Wan, Qi ^a,b   Ho, Wen Zhe ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Wuhan Centers for Disease Prevention and Control   (China)

^e CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DIAMORPHINE; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 5; MITOGEN ACTIVATED PROTEIN KINASE P38; MORPHINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; HEPATITIS C VIRUS; HEROIN DEPENDENCE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; VIRUS REPLICATION;

EID: 34548085416     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/520093     Document Type: Article

References (50)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S-5S.
2. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999; 31:88-91.
3. Thomas DL, Cannon RO, Shapiro CN, Hook EW III, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994; 169:990-5.
4. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107:2S-9S.
5. Haverkos HW, Lange WR. From the Alcohol, Drug Abuse, and Mental Health Administration: serious infections other than human immunodeficiency virus among intravenous drug abusers. J Infect Dis 1990; 161:894-902.
6. Louria DB, Hensle T, Rose J. The major medical complications of heroin addiction. Ann Intern Med 1967; 67:1-22.
7. Day C, Ross J, Dolan K. Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination? Drug Alcohol Rev 2003; 22:317-21.
8. Backmund M, Meyer K, Wachtler M, Eichenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 2003; 18:563-8.
9. Chisari FV. Unscrambling hepatitis C virus-host interactions. Nature 2005; 436:930-2.
10. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99:15661-8.
11. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436:946-52.
12. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436:939-45.
13. Chang SL, Wu GD, Patel NA, Vidal EL, Fiala M. The effects of interaction between morphine and interleukin-1 on the immune response. Adv Exp Med Biol 1998; 437:67-72.
14. Eisenstein TK, Hilburger ME. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J Neuroimmunol 1998; 83:36-44.
15. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001; 62:111-23.
16. Roy S, Cain KJ, Chapin RB, Charboneau RG, Barke RA. Morphine modulates NF kappa B activation in macrophages. Biochem Biophys Res Commun 1998; 245:392-6.
17. Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 1998; 10:383-90.
18. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791-6.
19. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309:623-6.
20. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102:9294-9.
21. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290:1972-4.
22. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002; 76:13001-14.
23. Li Y, Zhang T, Douglas SD, et al. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003; 163:1167-75.
24. Lin RT, Yang L, Arguello M, Penafuerte C, Hiscott J. A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization. J Biol Chem 2005; 280:3088-95.
25. Lin R, Mamane Y, Hiscott J. Multiple regulatory domains control IRF-7 activity in response to virus infection. J Biol Chem 2000; 275:34320-7.
26. Zhang T, Lin RT, Li Y, et al. Hepatitits C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology 2005; 42:819-27.
27. Kato T, Furusaka A, Miyamoto M, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 2001; 64:334-9.
28. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001; 75:4614-24.
29. Yang JH, Lai JP, Douglas SD, Metzger D, Zhu XH, Ho WZ. Real-time RT-PCR for quantitation of hepatitis C virus RNA. J Virol Methods 2002; 102:119-28.
30. Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1997; 8:293-312.
31. Mamane Y, Heylbroeck C, Genin P, et al. Interferon regulatory factors: the next generation. Gene 1999; 237:1-14.
32. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:1506-10.
33. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321:1501-6.
34. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332:1457-62.
35. Kato T, Date T, Miyamoto M, et al. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol 2005; 43:5679-84.
36. Nair MP, Schwartz SA, Polasani R, Hou J, Sweet A, Chadha KC. Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol 1997; 4:127-32.
37. Stoll-Keller F, Schmitt C, Thumann C, Schmitt MP, Caussin C, Kirn A. Effects of morphine on purified human blood monocytes: modifications of properties involved in antiviral defences. Int J Immunopharmacol 1997; 19:95-100.
38. Barnes B, Lubyova B, Pitha PM. On the role of IRF in host defense. J Interferon Cytokine Res 2002; 22:59-71.
39. Au W-C, Pitha PM. Recruitment of multiple interferon regulatory factors and histone acetyltransferase to the transcriptionally active interferon a promoters. J Biol Chem 2001; 276:41629-37.
40. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001; 276:23382-90.
41. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 1998; 17:6660-9.
42. Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002; 2:675-87.
43. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002; 22:5721-40.
44. Wang CQ, Li Y, Douglas SD, et al. Morphine withdrawal enhances hepatitis C virus replicon expression. Am J Pathol 2005; 167:1333-40.
45. Ishida H, Ohkawa K, Hosui A, et al. Involvement of p38 signaling pathway in interferon-alpha-mediated antiviral activity toward hepatitis C virus. Biochem Biophys Res Commun 2004; 321:722-7.
46. Li Y, Sassano A, Majchrzak B, et al. Role of p38alpha Map kinase in type I interferon signaling. J Biol Chem 2004; 279:970-9.
47. Mayer IA, Verma A, Grumbach IM, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 2001; 276:28570-7.
48. Goh KC, Haque SJ, Williams BR. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 1999; 18:5601-8.
49. Hu S, Sheng WS, Lokensgard JR, Peterson PK. Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. J Infect Dis 2005; 191:886-9.
50. Mahajan SD, Schwartz SA, Aalinkeel R, Chawda RP, Sykes DE, Nair MP. Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol 2005; 115:323-32.